Priors on between-study heterogeneity in Bayesian meta-analysis models: A simulation study using Hamiltonian Monte Carlo sampling

Dunnewind N¹, Ainsworth C², Ren S³, Kroep S¹

¹OPEN Health HEOR & Market Access, Rotterdam, The Netherlands, ²OPEN Health HEOR & Market Access, London, UK, ³University of Sheffield, Sheffield, UK



SA80

INTRODUCTION & OBJECTIVE

- Meta-analysis (MA) plays a crucial role in health economic and outcomes research. Random effects (RE) models in MA allow for heterogeneity in treatment effects between studies.
- In a Bayesian framework, prior beliefs are assigned to model parameters, including the between-study heterogeneity, often using non-informative priors.¹
- Previous research² explored the use of different priors for the heterogeneity parameter on MA results using WinBUGS³ (Gibbs sampling).
- Hamiltonian Monte Carlo (HMC) sampling, implemented in Stan⁴, is used increasingly more often in recent years and should be more efficient than Gibbs sampling.⁵

RESULTS

Case study

- The case study demonstrated that priors with zero density at plausible values results in divergent transitions (Figure 1) and may therefore lead to biased results.⁹
- For most priors, the non-centred parametrization decreased the number of divergent transitions.

Figure 1. Divergent transitions as percentage of samples per prior and parameterization.



OBJECTIVES

- The aim of this study was to replicate Lambert et al. (2005)² instead using HMC sampling.
- Further, the study aimed to expand previous research by investigating performance of additional priors on the between-study heterogeneity parameter (i.e., an informative prior and improper flat prior), and the use of non-centred model parameterization.
- Finally, the study sought to explore model fit under RE models (for each prior investigated) and compare with that for fixed effect (FE) models.

METHODS

Model

- Three meta-analysis models were fitted:
 - An RE model with centred parameterization, as used for example in NICE technical support documents:¹

 $y_i \sim N(\mu_i, s_i^2)$ $\mu_i \sim N(\theta, \tau^2)$

where y_i and s_i are the observed log-odds ratio and its standard error for study i, μ_i is the modelled log-odds ratio, τ is the between-study standard deviation (SD) and θ is the pooled log-odds ratio.

- An RE model with non-centred parameterization:⁵

$$y_i \sim N(\theta + \tau \mu_i, s_i^2)$$
 $\mu_i \sim N(0,1)$

- An FE model:

 $y_i \sim N(\theta, s_i^2)$

- Models were implemented in Stan.⁴ Four chains with 2000 iterations (1000 warmup) each were sampled, with the target average acceptance probability set to 0.98.
- An uninformative prior was placed on the pooled log-odds ratio: $\theta \sim N(0,100)$.
- Fourteen priors for the between-study SD, varying in distribution and level of information, were tested (Table 1).
- Prior 0 is an improper flat prior.
- Prior 13 is the empirical Bayes⁶ prior.

Simulation study

- Based on the observations in the case study, the non-centred parametrization and priors with no or very few divergent transitions were used in the simulation study.
- Figure 2 presents pairwise comparisons of between-study heterogeneity priors for the five-study scenario, illustrating the impact on the SD of the pooled log-odds ratio.
- Within each pairwise comparison, dots (replications) which lie around the diagonal indicate similar results for the two priors being compared.
- Conversely, dots which are consistently above (or below) the diagonal indicate a higher (or lower) SD of the pooled log-odds ratio for the row prior versus column prior in the comparison, i.e., more (or less) uncertainty in the treatment effect estimate under the row prior.
- For example, in the pairwise comparison of informative prior 14 versus flat prior 0 (upper right subplot), there is decreased uncertainty in the treatment effect for prior 14 (dots are consistently above the diagonal).
- Among simulation scenarios, RE models with a gamma prior on precision (1), an empirical Bayes prior (13) and an informative prior on variance (14) were most likely to be favoured over FE models (lowest DIC).
- Convergence issues were more prominent when using the improper flat prior (0), the non-informative normal prior on SD (11), the non-informative priors on SD and variance (5, 9) and the non-informative Pareto prior on precision (7), especially in scenarios with fewer studies and higher true SD.
- The non-informative uniform prior on variance (5) still resulted in many divergent transitions, especially in
- Prior 14 is the informative prior suggested by Turner et al.⁷ for a pharmacological vs placebo comparison and a subjective outcome.

Table 1. Between-study SD priors

0.	$\boldsymbol{\tau} \sim \text{Uniform}(0, \infty)$	8.	$\frac{1}{\tau^2} \sim \text{Pareto}(1, 0.25)$
1.	$\frac{1}{\tau^2} \sim \text{Gamma}(0.001, 0.001)$	9.	$ au \sim Uniform(0, 100)$
2.	$\frac{1}{\tau^2} \sim \text{Gamma}(0.1, 0.1)$	10	$\tau \sim \text{Uniform}(0, 2)$
3.	$\log \tau^2 \sim \text{Uniform}(-10, 10)$	11.	$ au \sim N(0, 100); au > 0$
4.	$\log \tau^2 \sim \text{Uniform}(-10, 1.386)$	12.	$ au \sim N(0, 1); au > 0$
5.	$ au^2 \sim ext{Uniform}(1/1000$, $1000)$	13.	$\tau \sim \text{LogLogistic}(S_0); S_0 = \sqrt{K/\sum s_i^{-2}}$
6.	$\tau^2 \sim \text{Uniform}(1/1000, 4)$	14.	$ au^2 \sim LogNormal(-2.13, 1.58); au > 0$
7.	$\frac{1}{\tau^2} \sim \text{Pareto}(1, 0.001)$		

Note: Lambert et al. (2005) used priors 1 to $13.^2 \ \kappa$ is the number of studies.

The same case study and simulation study setup as in Lambert et al. (2005) were used.²

Case study

• Models were first fitted on data from five studies comparing the effects of short course versus long course antibiotics for acute otitis media.⁸

scenarios with a true SD of 0.001.

Figure 2. Scatter plot matrix comparing all selected between-study SD prior distributions for the five-study scenario with a between-study SD of 0.3, displaying the posterior SD of the pooled log-odds ratio. Each point represents a simulation replication.



CONCLUSIONS

Simulation study

- One thousand simulated dichotomous outcome datasets, with differing true between-study SD and number of studies, were evaluated.
- A random study effect was drawn from a normal distribution with mean zero, and a varied SD across three scenarios (0.001, 0.3, or 0.8).
- The placebo log-odds, log-odds ratio and the random study effect were summed to obtain the odds ratio of the treatment arm, and the number of events is drawn from a binomial distribution. Scenarios with 5, 10 and 30 studies were evaluated, with 100 to 500 patients in each of the two study arms.
- Results were compared by assessing the bias, coverage, deviance information criterion (DIC), convergence (based on R-hats and Monte Carlo standard errors) and divergent transitions (an HMC diagnostic indicating Markov chain Monte Carlo estimators may be invalid and biased⁸).
- Findings are very similar to results presented by Lambert et al. (2005)², despite the different parameterization and (more efficient⁵) sampling method.
- Selection of an appropriate between-study heterogeneity prior is crucial as it impacts the posterior treatment effect, particularly when dealing with a low number of studies.
- Caution must be exercised to avoid bias when using informative priors.
- In future studies, adopting non-centred model parameterization as standard practice is advisable over centred parameterization.
- HMC diagnostics, such as divergent transitions, are helpful and show that priors with zero density at plausible values should be avoided.

REFERENCES

- 1. Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials. London: National Institute for Health and Care Excellence (NICE); April 2014.
- 2. Lambert PC, Sutton AJ, Burton PR, Abrams KR, Jones DR. How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS. Stat Med. 2005;24(15):2401-2428.

3. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS-a Bayesian modelling framework: concepts, structure, and extensibility. *Statistics and computing*. 2000;10:325-337.
4. Stan Development Team. RStan: The R interface to Stan. Published online 2022. https://mc-stan.org.

- 5. Betancourt M, Girolami M. Hamiltonian Monte Carlo for Hierarchical Models. *Current Trends in Bayesian Methodology with Applications*. 2015;79(30):2-4.
- 6. DuMouchel W, Normand S. Computer-Modeling and Graphical Strategies for Meta-Analysis. In: *Meta-Analysis in Medicine and Health Policy*. 2000:119-164.
- 7. Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins JP. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. *Int J Epidemiol*. 2012;41(3):818-827.8.
- 8. Venekamp RP, Sanders SL, Glasziou PP, Del Mar CB, Rovers MM. Antibiotics for acute otitis media in children. *Cochrane Database Syst Rev.* 2015;2015(6):CD0002199.
- 9. Betancourt M. A conceptual introduction to Hamiltonian Monte Carlo. Published online 2018. https://arxiv.org/abs/1701.02434

Presented at ISPOR Europe 2023